Last reviewed · How we verify

Arterial embolus and thrombosis — Treatment Landscape & Competitive Intelligence

Arterial embolus and thrombosis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Arterial embolus and thrombosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Eliquis apixaban Bristol-Myers Squibb Factor Xa inhibitor Factor Xa (FXa) 2012-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bristol-Myers Squibb · 1 drug in Arterial embolus and thrombosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Arterial embolus and thrombosis:

Cite this brief

Drug Landscape (2026). Arterial embolus and thrombosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/arterial-embolus-and-thrombosis. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing